skip to Main Content

Pharma Reputations: Managing Perceptions

  • 14 août 2012

Geneva-based Covalence, a company that markets the information system, EthicalQuote, has observed that pharma is not keeping pace with other industries in terms of the overall balance of global good and bad news coverage in four broad ethical areas: labour…

More

Drug Firms Say They’ll Take Closer Look at the Docs They Pay

  • 18 novembre 2010

Several of the nation's largest pharmaceutical companies said they plan to tighten screening of physicians who promote their drugs after ProPublica reported last month that more than 250 of them had been sanctioned for misconduct. Eli Lilly and Co. said…

More

Eli Lilly Adds Support for Drug Transparency Laws

  • 27 mai 2008

Amid increasing governmental and professional concerns about payments to physicians by pharmaceutical companies, major drug manufacturer Eli Lilly announced its support for legislation to increase public trust in the healthcare industry. Independent studies have shown a significant financial link between…

More

The Burden of Innovation – Covalence Pharmaceutical Industry Report 2007

  • 29 août 2007

Pharmaceutical companies carry increasing ethical risks related to innovation, states a report released on 29 August 2007 by Geneva-based ethical reputation research firm Covalence, Covalence Pharmaceutical Industry Report 2007. These innovation-related risks deal with intellectual property rights, drug pricing, clinical…

More

After Sanctions, Doctors Get Drug Company Pay

  • 3 juin 2007

A decade ago the Minnesota Board of Medical Practice accused Dr. Faruk Abuzzahab of a “reckless, if not willful, disregard” for the welfare of 46 patients, 5 of whom died in his care or shortly afterward. The board suspended his…

More
Back To Top